Welcome!

News Feed Item

YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012

- 68% transfusion independence response rate and 37% durable spleen response rate -

MISSISSAUGA, ON, Dec. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported updated results from the 166 patient Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were presented this afternoon in an oral session at the 54th Annual Meeting of the American Society of Hematology underway in Atlanta, Georgia.

  • 68% durable 12-week transfusion independence response rate with a maximal duration of response approaching three years and ongoing.
  • The percentage of patients requiring transfusions decreased substantially, from 44% at baseline to below 10% at week 40 of treatment.
  • 37% durable spleen response per IWG-MRT* with a maximal duration of response of nearly 2.5 years and ongoing.
  • The majority of subjects achieved a complete resolution or marked improvement of common constitutional symptoms.
  • The majority of adverse events were Grade 1.

"These data continue to demonstrate that treatment with CYT387 results in significant, durable responses in transfusion dependency, splenomegaly and constitutional symptoms," said Dr. Nick Glover, President and CEO of YM BioSciences. "The benefits CYT387 produces are highly encouraging for patients with myelofibrosis and underscore the clinical potential of this drug."

*International Working Group for Myelofibrosis Research and Treatment

Phase I/II Core Study Results

Study Design and Subject Disposition
The Core Study consisted of nine 28-day treatment cycles where CYT387 was orally self-administered, primarily at dosages of 150 mg once-daily (QD), 300 mg QD or 150 mg twice-daily (BID). Patients who tolerated and benefited from the drug could continue to receive CYT387 for an indefinite period beyond the Core Study in an Extension Study. The 300 mg QD dosing regimen has been selected for use in the anticipated Phase III clinical development program.

The median follow-up time for patients in the Core Study and Extension Study is 16.9 months (range: 0.8 - 34.2 months; ongoing). During the Core Study, 42 patients (25%) discontinued the study, eight for possibly or probably related adverse events, for an overall retention rate of 75%.

Subject Baseline Characteristics
The majority of the 166 patients enrolled across the six study sites have primary myelofibrosis (63%); 22% have post-polycythemia vera myelofibrosis and 15% have post-essential thrombocythemia myelofibrosis. Other patient characteristics include:

  • DIPSS-Plus category: Int-1 - 10%; Int-2 - 62%; High - 28%
  • RBC (Red blood cell) transfusion-dependent: 44%
  • Palpable splenomegaly >10 cm: 79%
  • Patients who had received previous therapies, including other JAK inhibitors (13%) and IMiDs (9%).

Transfusion Independence Response
Of the 68 evaluable patients who were transfusion dependent at baseline, 68% became transfusion independent for a minimum of 12 weeks during the Core Study. The median duration of the transfusion-free period has not yet been reached (range: 85 - 988 days, ongoing). Of the transfusion dependent patients who did not achieve a full transfusion independence response, 23% achieved at least a 50% reduction in transfusion requirement in any 3-month period.

The percentage of patients requiring transfusions decreased substantially during the study, from 44% at baseline to below 10% at week 40 of treatment.

Of the 28 evaluable patients who were transfusion dependent at baseline and dosed at 300 mg QD, 75% have become transfusion independent for a minimum of 12 weeks.

Three additional patients achieved a 12-week transfusion independence response during the Extension Study.

Spleen Response
Of the 145 patients evaluable for spleen response by palpation, 37% achieved a response per IWG-MRT. The median duration of spleen response reported was 744 days (range: 56 - 859 days, ongoing). Three additional subjects achieved spleen response during the Extension Study.

During the Core Study, 50% of evaluable patients achieved more than a 50% maximal decrease in spleen size from baseline, with 87% achieving more than a 25% maximal decrease.

Of the 51 patients who were evaluable for spleen response and dosed at 300 mg QD, 39% achieved a response per IWG-MRT.

In the Core Study, 11 patients were evaluable for spleen response by MRI. The response rate at six months was 45% by MRI (defined as a 35% decrease in spleen volume) and the median splenic decrease from baseline at six months was -41% by volume measured by MRI.

Constitutional Symptoms Response
The majority of patients reporting constitutional symptoms at baseline demonstrated a Complete Resolution or Marked Improvement of their symptoms, including night sweats, pruritus and bone pain.

Safety Results
CYT387 is well tolerated in myelofibrosis patients for dosing periods currently up to three years and ongoing. The majority of adverse events were Grade 1. Common reported adverse effects include thrombocytopenia; transient, mild dizziness; mild peripheral neuropathy; and abnormalities in liver/pancreas-related laboratory tests. Treatment-emergent anemia and neutropenia were rarely observed.

Oral presentation and YM conference call:
The results from the Phase I/II study are being presented today at 5:15pm ET in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, Georgia. YM will also host a webcast meeting open to members of the investment community to discuss the results. This event will be held from 6:30-7:30am ET on Monday, December 10th in the Imperial Salon Room A of the Atlanta Marriott Marquis, 265 Peachtree Center Ave. NE, Atlanta, Georgia. Access to the webcast will be available from YM's website at www.ymbiosciences.com or at www.newswire.ca.

About CYT387:
CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, and as well in numerous other disorders including indications in hematology, oncology and inflammatory diseases. Myelofibrosis is a chronic debilitating disease in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory. Both the U.S. Food and Drug Administration (FDA) and the European Commission have designated CYT387 an Orphan Drug for the treatment of myelofibrosis.

About YM BioSciences
YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. Positive interim results have been reported from a Phase I/II trial of CYT387 in 166 patients with myelofibrosis. YM's portfolio also includes several preclinical programs underway with candidates from its library of novel compounds identified through internal research conducted at YM BioSciences Australia.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
Given the popularity of the containers, further investment in the telco/cable industry is needed to transition existing VM-based solutions to containerized cloud native deployments. The networking architecture of the solution isolates the network traffic into different network planes (e.g., management, control, and media). This naturally makes support for multiple interfaces in container orchestration engines an indispensable requirement.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, presented an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He then expounded on the industry issues he frequently came up against as an analyst, and ...
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...
As more and more companies are making the shift from on-premises to public cloud, the standard approach to DevOps is evolving. From encryption, compliance and regulations like GDPR, security in the cloud has become a hot topic. Many DevOps-focused companies have hired dedicated staff to fulfill these requirements, often creating further siloes, complexity and cost. This session aims to highlight existing DevOps cultural approaches, tooling and how security can be wrapped in every facet of the bu...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...